KOD Quote, Financials, Valuation and Earnings

ADMA Biologics, Inc. has a net margin of -- compared to Kodiak Sciences, Inc.'s net margin of 35.48%. Kodiak Sciences, Inc.'s return on equity of -201.8% beat ADMA Biologics, Inc.'s return on equity of 36.2%.

Kodiak Sciences, Inc. has a consensus price target of $51.67, signalling upside risk potential of 39.64%. On the other hand ADMA Biologics, Inc. has an analysts' consensus of $23.50 which suggests that it could grow by 154.05%. Given that ADMA Biologics, Inc. has higher upside potential than Kodiak Sciences, Inc., analysts believe ADMA Biologics, Inc. is more attractive than Kodiak Sciences, Inc..

Kodiak Sciences, Inc. has a beta of 2.613, which suggesting that the stock is 161.277% more volatile than S&P 500. In comparison ADMA Biologics, Inc. has a beta of 0.510, suggesting its less volatile than the S&P 500 by 48.977%.

Kodiak Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. ADMA Biologics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kodiak Sciences, Inc. pays -- of its earnings as a dividend. ADMA Biologics, Inc. pays out -- of its earnings as a dividend.

Kodiak Sciences, Inc. quarterly revenues are --, which are smaller than ADMA Biologics, Inc. quarterly revenues of $139.2M. Kodiak Sciences, Inc.'s net income of -$61.5M is lower than ADMA Biologics, Inc.'s net income of $49.4M. Notably, Kodiak Sciences, Inc.'s price-to-earnings ratio is -- while ADMA Biologics, Inc.'s PE ratio is 15.44x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kodiak Sciences, Inc. is -- versus 4.45x for ADMA Biologics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Catalyst Pharmaceuticals, Inc. has a net margin of -- compared to Kodiak Sciences, Inc.'s net margin of 34.53%. Kodiak Sciences, Inc.'s return on equity of -201.8% beat Catalyst Pharmaceuticals, Inc.'s return on equity of 25.2%.

Kodiak Sciences, Inc. has a consensus price target of $51.67, signalling upside risk potential of 39.64%. On the other hand Catalyst Pharmaceuticals, Inc. has an analysts' consensus of $34.00 which suggests that it could grow by 45.3%. Given that Catalyst Pharmaceuticals, Inc. has higher upside potential than Kodiak Sciences, Inc., analysts believe Catalyst Pharmaceuticals, Inc. is more attractive than Kodiak Sciences, Inc..

Kodiak Sciences, Inc. has a beta of 2.613, which suggesting that the stock is 161.277% more volatile than S&P 500. In comparison Catalyst Pharmaceuticals, Inc. has a beta of 0.746, suggesting its less volatile than the S&P 500 by 25.388%.

Kodiak Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Catalyst Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kodiak Sciences, Inc. pays -- of its earnings as a dividend. Catalyst Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Kodiak Sciences, Inc. quarterly revenues are --, which are smaller than Catalyst Pharmaceuticals, Inc. quarterly revenues of $152.6M. Kodiak Sciences, Inc.'s net income of -$61.5M is lower than Catalyst Pharmaceuticals, Inc.'s net income of $52.7M. Notably, Kodiak Sciences, Inc.'s price-to-earnings ratio is -- while Catalyst Pharmaceuticals, Inc.'s PE ratio is 13.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kodiak Sciences, Inc. is -- versus 5.06x for Catalyst Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Revolution Medicines, Inc. has a net margin of -- compared to Kodiak Sciences, Inc.'s net margin of --. Kodiak Sciences, Inc.'s return on equity of -201.8% beat Revolution Medicines, Inc.'s return on equity of -59.94%.

Kodiak Sciences, Inc. has a consensus price target of $51.67, signalling upside risk potential of 39.64%. On the other hand Revolution Medicines, Inc. has an analysts' consensus of $133.70 which suggests that it could grow by 44.53%. Given that Revolution Medicines, Inc. has higher upside potential than Kodiak Sciences, Inc., analysts believe Revolution Medicines, Inc. is more attractive than Kodiak Sciences, Inc..

Kodiak Sciences, Inc. has a beta of 2.613, which suggesting that the stock is 161.277% more volatile than S&P 500. In comparison Revolution Medicines, Inc. has a beta of 0.991, suggesting its less volatile than the S&P 500 by 0.875%.

Kodiak Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Revolution Medicines, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kodiak Sciences, Inc. pays -- of its earnings as a dividend. Revolution Medicines, Inc. pays out -- of its earnings as a dividend.

Kodiak Sciences, Inc. quarterly revenues are --, which are smaller than Revolution Medicines, Inc. quarterly revenues of --. Kodiak Sciences, Inc.'s net income of -$61.5M is higher than Revolution Medicines, Inc.'s net income of -$364.9M. Notably, Kodiak Sciences, Inc.'s price-to-earnings ratio is -- while Revolution Medicines, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kodiak Sciences, Inc. is -- versus -- for Revolution Medicines, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Tango Therapeutics, Inc. has a net margin of -- compared to Kodiak Sciences, Inc.'s net margin of 29.52%. Kodiak Sciences, Inc.'s return on equity of -201.8% beat Tango Therapeutics, Inc.'s return on equity of -50.42%.

Kodiak Sciences, Inc. has a consensus price target of $51.67, signalling upside risk potential of 39.64%. On the other hand Tango Therapeutics, Inc. has an analysts' consensus of $20.44 which suggests that it could grow by 6.15%. Given that Kodiak Sciences, Inc. has higher upside potential than Tango Therapeutics, Inc., analysts believe Kodiak Sciences, Inc. is more attractive than Tango Therapeutics, Inc..

Kodiak Sciences, Inc. has a beta of 2.613, which suggesting that the stock is 161.277% more volatile than S&P 500. In comparison Tango Therapeutics, Inc. has a beta of 1.761, suggesting its more volatile than the S&P 500 by 76.144%.

Kodiak Sciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Tango Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Kodiak Sciences, Inc. pays -- of its earnings as a dividend. Tango Therapeutics, Inc. pays out -- of its earnings as a dividend.

Kodiak Sciences, Inc. quarterly revenues are --, which are smaller than Tango Therapeutics, Inc. quarterly revenues of --. Kodiak Sciences, Inc.'s net income of -$61.5M is lower than Tango Therapeutics, Inc.'s net income of -$38.7M. Notably, Kodiak Sciences, Inc.'s price-to-earnings ratio is -- while Tango Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Kodiak Sciences, Inc. is -- versus 35.77x for Tango Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.